Hennion & Walsh Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,763	Closed	-$2.77M	–	894
2023 Q4	$2.77M	Buy	8,763 +739	+9%	+$144K	0.16%	186
2023 Q3	$1.36M	Buy	8,024 +218	+3%	+$41K	0.09%	285
2023 Q2	$1.69M	Sell	7,806 -223	-3%	-$47.8K	0.1%	245
2023 Q1	$1.46M	Buy	8,029 +114	+1%	+$21.8K	0.09%	274
2022 Q4	$1.55M	Buy	7,915 +1,034	+15%	+$222K	0.1%	251
2022 Q3	$1.55M	Buy	6,881 +3,072	+81%	+$622K	0.1%	234
2022 Q2	$482K	Buy	+3,809	New	+$438K	0.03%	491

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Hennion & Walsh Asset Management's KRTX Position: Q1 2024 in Review

Hennion & Walsh Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 8,763 shares — an estimated $2.77M sold.

Hennion & Walsh Asset Management first reported a position in KRTX in Q2 2022 and held it in 7 quarters. The position peaked at $2.77M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Hennion & Walsh Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Hennion & Walsh Asset Management sold 8,763 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.77M.
Hennion & Walsh Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
Hennion & Walsh Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $2.77M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q1 2024, filed 17 Apr 2024.